⌕
ImmunityBio · IBRX · Nasdaq
Tenet 51 · Mixed
Compare
$6.70+7.03%At closeTenet 51 · Mixed
$6.70+0.44 (+7.03%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

ImmunityBio (IBRX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

8 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~231.9%/yr (FY21→FY25), net margin −310.2%. Worth your attention in FY25: Share count (+136.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲668.3%
113.3
FY21→FY25CAGR +231.9%/yr
Net income ($M)▲15.0%
−351.4
FY21→FY25CAGR —
Free cash flow ($M)▲22.3%
−309.2
FY21→FY25CAGR —
Diluted EPS▲38.7%
−0.38
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+136.3%

389.2mn → 919.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$4.3M

−38.3% YoY in FY25 · 3.8% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)113288.0Revenue−753.0COGS112535.0Gross profit−218559.0R&D−150003.0SG&A−256027.0Op income−95371.0Tax & other−351398.0Net income

-310¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 100.0% → 99.3%. Net margin -310.2% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
182,572.0113,288.014,745.0622.0240.0934.0▲668.3%+231.9%
Cost of revenue
2,209.0753.00.00.00.00.0——
Gross profit
180,363.0112,535.0—A—A—A934.0——
Research & development
264,202.0218,559.0190,144.0232,366.0248,149.0195,958.0▲14.9%+2.8%
Selling, general & admin
190,319.0150,003.0168,783.0129,620.0102,708.0135,256.0▼11.1%+2.6%
Total operating expenses
454,521.0368,562.0358,927.0362,872.0351,538.0331,214.0▲2.7%+2.7%
Operating incomefeeds ROC rank
−274,158.0−256,027.0−344,182.0−362,250.0−351,298.0−330,280.0▲25.6%—
Other income, net
−835,678.0−95,580.0−69,463.0−221,642.0−65,988.0−19,559.0——
Pretax income
−1,109,836.0−351,607.0−413,645.0−583,892.0−417,286.0−349,839.0▲15.0%—
Income tax
−170.0−135.00.0−40.034.09.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−1,109,654.0−351,398.0−413,564.0−583,196.0−416,567.0−349,848.0▲15.0%—
Per share
Diluted EPSbuyback-sensitive
−1.08−0.38−0.62−1.15−1.04−0.89▲38.7%—
Diluted shares (bn)
1.060.920.700.510.400.39▲31.3%+24.0%
Margins
Gross margin98th pct in Healthcare
98.8%99.3%—A—A—A100.0%——
Operating margin
−150.2%−226.0%−2334.2%−58239.5%−146374.2%−35361.9%▲2108.2pp+35135.9pp
Net margin6th pct in Healthcare
−607.8%−310.2%−2804.8%−93761.4%−173569.6%−37457.0%▲2494.6pp+37146.8pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY13 – FY20 · 8 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-23 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was ImmunityBio's revenue last fiscal year?

ImmunityBio reported revenue of $113.3M in fiscal 2025, up 668.3% from fiscal 2024.

What was ImmunityBio's net income?

ImmunityBio reported net income of −$351.4M in fiscal 2025, a net margin of −310.2%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.